Key Takeaway: Nurix is advancing its portfolio of therapies aimed at treating cancer and autoimmune diseases through novel scientific insights. The company emphasizes its dedication to developing breakthrough therapies and enhancing its protein degradation resources. This strategic focus positions Nurix to potentially outmatch current treatment options.
Price reaction · baseline $13.83 (2024-04-05T13:53:00.000Z) · hit during market hours · 5 other NRIX headline(s) in the window, move may be shared
day 0 close · peak
+0.5%
Market Sentiment Analysis
POSITIVE FACTORS
Focus on novel scientific insights for cancer treatment.
Advancement of a multi-modal portfolio of therapies.
Commitment to addressing cancer and autoimmune diseases.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma
Full Press Release Details
RESOURCE LIBRARY
RESOURCE LIBRARY
At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.
Filter by
Frequently Asked Questions
What is Nurix focused on?
Nurix is focused on translating novel scientific insights into therapies for cancer and autoimmune diseases.
What type of therapies is Nurix developing?
Nurix is advancing a multi-modal portfolio of wholly owned and partnered assets.
What resources does Nurix provide?
Nurix offers protein degradation resources aimed at enhancing cancer treatment.